Showing results (281-290 of 312) with videos related to

Sort By:
Pageof 32
ESMO Open|November 3, 2023
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO studyC B Westphalen, J Federer-Gsponer, C Pauli, et al.
JCO Precision Oncology|October 5, 2020
CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1-Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-CodeletionErik A Williams, Radwa Sharaf, Brennan Decker, et al.
Nature Communications|December 5, 2022
Tissue and liquid biopsy profiling reveal convergent tumor evolution and therapy evasion in breast cancerSmruthy Sivakumar, Dexter X Jin, Hanna Tukachinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 11, 2019
The Genomic Landscape of Merkel Cell Carcinoma and Clinicogenomic Biomarkers of Response to Immune Checkpoint Inhibitor TherapyTodd C Knepper, Meagan Montesion, Jeffery S Russell, et al.
JCO Precision Oncology|September 28, 2023
Pan-Cancer Analysis of Copy-Number Features Identifies Recurrent Signatures and a Homologous Recombination Deficiency Biomarker to Predict Poly (ADP-Ribose) Polymerase Inhibitor ResponseJay A Moore, Kuei-Ting Chen, Russell Madison, et al.
NPJ Precision Oncology|December 9, 2022
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumorsJessica K Lee, Smruthy Sivakumar, Alexa B Schrock, et al.
Medrxiv : the Preprint Server for Health Sciences|March 23, 2026
Cancer genomic profiling predicts pathogenicity of BRCA1 and BRCA2 variantsOlga Kondrashova, Rebecca L Johnston, Michael T Parsons, et al.
The Journal of Molecular Diagnostics : JMD|January 4, 2026
Phenotypic POLE variant classification identifies patients who may have favorable prognosis and benefit from immunotherapyRachel B Keller-Evans, Zoe Fleischmann, Smruthy Sivakumar, et al.
Elife|July 5, 2022
Genomic landscape of lymphatic malformations: a case series and response to the PI3Kα inhibitor alpelisib in an N-of-1 clinical trialMontaser F Shaheen, Julie Y Tse, Ethan S Sokol, et al.
ESMO Open|December 6, 2025
Homologous recombination repair status in advanced endometrial cancer: an exploratory biomarker analysis from the randomized, phase II MITOEND 3 trialM Bartoletti, A Passarelli, A Fagotti, et al.
Pageof 32